Abstract:
A communications system includes a first reception device and a transmission device. The transmission device includes a modulator operable to modulate a plurality of subcarriers using a signal series obtained by multiplexing a first signal series to be transmitted to the first reception device and a second signal series to be transmitted to a plurality of reception devices including the first reception device in a communications area of the transmission device and a transmitter operable to transmit the modulation signals. The first reception device includes a demodulator operable to regenerate the first signal series and the second signal series.
Abstract:
A mobile terminal having a receive diversity function using a plurality of receive antennas, having a calculation section which combines respective level measurement results of the receive antennas and calculates a level measurement value after being combined as the level measurement result of the mobile terminal.
Abstract:
An interleaving apparatus comprises a first storing unit for storing data to be transmitted and a first control unit for controlling the first storing unit so that the data to be transmitted is outputted from the first storing unit with the data to be transmitted arranged in a matrix and at least either columns or rows of the data to be transmitted randomly rearranged, facilitating the interleaving. The result is that biased distribution of data, which leads to degradation of the transmission quality, can be prevented relatively easily in a simple structure.
Abstract:
An n-bit binary value corresponding to an amount of phase shift d is assigned to an SREG, and a shift operation is performed. An n-bit vector value corresponding to a decimal value “1” is assigned to an LAT as an initial value. Thereafter, the input from an SW is sequentially stored. An MUL performs a square operation within a Galois field GF (2n) for the output of the LAT. A DBL performs a double operation within the Galois field GF (2n) for the output of the MUL. The SW selects either of the outputs of the MUL and the DBL according to the output value from the MSB side of the SREG. After the shift operation and the latch operation are performed a number of times n, the n-bit output of the LAT is output as respective phase shift coefficients b0 through bn−1.
Abstract:
A piperdine derivative having the formula (I) or a pharmacologically acceptable salt thereof:R.sup.1 --X--A--R.sup.2 (I)wherein R.sup.1 is selected from the group consisting of substituted or unsubstituted pyrazine, naphthalenedicarboxylic acid imide, bicyclo oct-5-ene-2,3-dicarboxylic acid imide and pyromellitimide;X is --(CH.sub.2).sub.n --, --O(CH.sub.2).sub.n --, --S(CH.sub.2).sub.n --, --NH(CH.sub.2).sub.n --, --SO.sub.1 NH(CH.sub.2).sub.n --, ##STR1## --CH.sub.2 NH(CH.sub.2).sub.n --, a group of the formula ##STR2## wherein n is an integer of 1 through 7 and R.sup.3 is hydrogen, lower alkyl or a benzyl, ##STR3## --O--CH.sub.2 CH.sub.2 CH.dbd. or ##STR4## R.sup.2 is hydrogen, lower alkyl, benzyl, benzyl substituted with hydroxy, methoxy or chlorine, benzoyl, benzyl with a fluorine substituent, pyridyl, 2-hydroxyethyl, pyridylmethyl or ##STR5## wherein Z represents a halogen atom.
Abstract:
In a paper sheet conveying and arranging apparatus, a low-friction paper sheet guide member (18) is located in a parallel relationship to a paper sheet advancing direction, and a rotating spiral contact (19) having an axis inclined with respect to a horizontal plane toward an upstream side from the line perpendicular to the paper sheet advancing direction and passing on the upstream side of the paper sheet guide member (18), is rotated with a distal end (19a) frictionally contacting the surface of the paper sheet guide member (18) so as to move the paper sheet downwardly away from the one end of a conveyer. The paper sheet is thereby turned from a horizontal posture to a vertical posture by a minimal turning operation.
Abstract:
A novel piperidine derivative is defined by the formula (I), including a slt thereof, ##STR1## wherein R.sup.1 denotes a univalent group derived from one selected among substituted or unsubstituted benzene, pyridine, pyrazine, indole, anthraquinone, quinoline, substituted or unsubstituted phthalimide, homophthalimide, pyridinecarboxylic acid imide, pyridine N-oxide, pyrazinedicarboxylic acid imide, naphthalenedicarboxylic acid imide, substituted or unsubstituted quinazolinedione, 1,8-naphthalimide, bicyclo [2.2.2] oct-5-ene-2,3-dicarboxylic acid imide and pyromerylimide,X denotes a group of the formula --(CH.sub.2).sub.n --, a group of the formula --O(CH.sub.2).sub.n --, a group of the formula --S(CH.sub.2).sub.n --, a group of the formula --NH(CH.sub.2).sub.n --, a group of the formula --SO.sub.2 NH(CH.sub.2).sub.n --, a group of the formula ##STR2## a group of the formula ##STR3## a group of the formula ##STR4## a group of the formula --CH.sub.2 NH(CH.sub.2).sub.n --, a group of the formula ##STR5## (in all the above formulas, n is an integer of 1 through 7 and R.sup.3 represents a lower alkyl group or a benzyl group), a group of the formula ##STR6## a group of the formula ##STR7## a group of the formula --O--CH.sub.2 CH.sub.2 CH= or a group of the formula ##STR8## the ring A denotes a group of the formula ##STR9## a group of the formula ##STR10## a group of the formula ##STR11## or a group of the formula ##STR12## and R.sup.2 denotes a hydrogen atom, a lower alkyl group, a substituted or unsubstituted benzyl group, a substituted or unsubstituted benzoyl group, a pyridyl group, a 2-hydroxyethyl group, a pyridylmetyl group or a group of the formula ##STR13## (wherein Z represents a halogen atom).
Abstract:
The novel vitamin E derivative provides an excellent antihyperlipemic effect and is defined by the formula (I): ##STR1## wherein R represents a nicotinoyl group; and m is an integer of from 2 to 5 while n is an integer of from 3 to 6, provided that n is larger than m.
Abstract:
A novel piperidine derivative is defined by the formula (I), including a salt thereof, ##STR1## wherein R.sup.1 denotes a univalent group derived from one selected among substituted or unsubstituted benzene, pyridine, pyrazine, indole, anthraquinone, quinoline, substituted or unsubstituted phthalimide, homophthalimide, pyridinecarboxylic acid imide, pyridine N-oxide, pyrazinedicarboxylic acid imide, naphthalenedicarboxylic acid imide, substituted or unsubstituted quinazolinedione, 1,8-naphthalimide, bicyclo [2.2.2] oct-5-ene-2,3-dicarboxylic acid imide and pyromerylimide,X denotes a group of the formula --(CH.sub.2).sub.n --, a group of the formula --O(CH.sub.2).sub.n --, a group of the formula --S(CH.sub.2).sub.n --, a group of the formula --NH(CH.sub.2).sub.n --, a group of the formula --SO.sub.2 NH(CH.sub.2).sub.n --, a group of the formula ##STR2## a group of the formula ##STR3## a group of the formula ##STR4## a group of the formula --CH.sub.2 NH(CH.sub.2).sub.n --, a group of the formula ##STR5## (in all the above formulas, n is an integer of 1 through 7 and R.sup.3 represents a lower alkyl group or a benzyl group), a group of the formula a group of the formula ##STR6## a group of the formula --O--CH.sub.2 CH.sub.2 CH.dbd. or a group of the formula ##STR7## the ring A denotes a group of the formula ##STR8## a group of the formula ##STR9## a group of the formula ##STR10## or a group of the formula andR.sup.2 denotes a hydrogen atom, a lower alkyl group, a substituted or unsubstituted benzyl group, a substituted or unsubstituted benzoyl group, a pyridyl group, a 2-hydroxyethyl group, a pyridylmethyl group or a group of the formula ##STR11## (wherein Z represents a halogen atom).
Abstract:
A 3-propenylcephem derivative of the following formula: ##STR1## wherein R.sub.1 represents a fluoro-substituted lower alkyl group or a cyano-substituted lower alkyl group, and A represents a cyclic or an acylic ammonio group, or a pharmaceutically acceptable salt thereof, exhibiting excellent anti-bacterial activities against both Gram-positive bacteria and Gram-negative bacteria; Process for the preparation thereof; Anti-bacterial composition; Intermediate for the 3-propenylcephem derivative; and Process for the preparation of the intermediate.